



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	LAFERTE S ET AL: "Monoclonal antibodies specific for human tumor-associated antigen 90K/Mac-2 Binding Protein:Tools to Examine Protein Conformation and Function" JOURNAL OF CELLULAR BIOCHEMISTRY, WILEY-LISS INC, US, vol. 77, no. 4, April 2000 (2000-04), pages 540-559, XP002975310 ISSN: 0730-2312 * abstract * * page 542, column 1, lines 11-33 * * page 546, column 2, lines 33-46 * * page 548, column 1, lines 7-14 * * page 555, column 2, lines 12-21 * * page 556, column 1, lines 13-23 *	1-12	INV. G01N33/574
Y	LAFERTE S ET AL: "CHARACTERIZATION OF A FAMILY OF STRUCTURALLY RELATED GLYCOPROTEINS EXPRESSING BETA1-6-BRANCHED ASPARAGINE-LINKED OLIGOSACCHARIDES IN HUMAN COLON CARCINOMA CELLS" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 283, no. 1, 1992, pages 193-201, XP009004873 ISSN: 0264-6021 * abstract * * page 199, column 1, line 13 - line 28 * * page 200, column 2, line 14 - line 24 *	1-12	TECHNICAL FIELDS SEARCHED (IPC) G01N
X	WO 01/81928 A (ST VINCENT'S HOSPITAL SYDNEY LIMITED; BREIT, SAMUEL, NORBERT; BROWN, D) 1 November 2001 (2001-11-01) * examples 1,7 * * claims 20-22 *	6-12	
----- -/--			
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search <b>The Hague</b>		Date of completion of the search <b>28 April 2006</b>	Examiner <b>Adida, A</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	

2

EPO FORM 1503 06.82 (F04C04)



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
A	US 2001/010908 A1 (BILLING-MEDEL PATRICIA A ET AL) 2 August 2001 (2001-08-02) ([0001], [0027], [0029], [0083], [0084], [0206]; claims 33,36, 53) * the whole document *	1-12	
A	US 5 427 914 A (DENNIS ET AL) 27 June 1995 (1995-06-27) * the whole document *	1-12	
A	BAUSKIN A R ET AL: "THE PROPEPTIDE OF MACROPHAGE INHIBITORY CYTOKINE (MIC-1), A TGF-BETA SUPERFAMILY MEMBER, ACTS AS A QUALITY CONTROL DETERMINANT FOR CORRECTLY FOLDED MIC-1" EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 19, no. 10, 2000, pages 2212-2220, XP001148765 ISSN: 0261-4189 * the whole document *	1-12	
D,A	DENNIS J W ET AL: "BETA1-6 BRANCHING OF ASN-LINKED OLIGOSACCHARIDES IS DIRECTLY ASSOCIATED WITH METASTASIS" SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, US, vol. 236, 3 April 1987 (1987-04-03), pages 582-585, XP002905214 ISSN: 0036-8075 * abstract * * page 585, column 1, line 60 - column 2, line 2 *	1-12	
-----			
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search		Date of completion of the search	Examiner
The Hague		28 April 2006	Adida, A
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone  Y : particularly relevant if combined with another document of the same category  A : technological background  O : non-written disclosure  P : intermediate document</p> <p>T : theory or principle underlying the invention  E : earlier patent document, but published on, or after the filing date  D : document cited in the application  L : document cited for other reasons  .....  &amp; : member of the same patent family, corresponding document</p>			

2

EPO FORM 1503 03.82 (F04C04)



### CLAIMS INCURRING FEES

The present European patent application comprised at the time of filing more than ten claims.

- Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

### LACK OF UNITY OF INVENTION

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet B

- All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1-12 (partially)



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

1. claims: 1-12 (partially)

A method of diagnosing a cancer comprising measuring the changes of N-linked sugar chains of PDF in a sample taken from a patient.

A kit for diagnosing cancers by measuring changes of sugar chains and expression of PDF, composed of antibody against PDF, matrix, buffer solution, coloring enzyme or fluorescent substance-labeled secondary antibody, coloring substrate and labeled antibody or labeled L4-PHA.

---

2. claims: 1-12 (partially)

A method of diagnosing a cancer comprising measuring the changes of N-linked sugar chains of peptidyl-prolyl cis-trans isomerase in a sample taken from a patient.

A kit for diagnosing cancers by measuring changes of sugar chains and expression of peptidyl-prolyl cis-trans isomerase, composed of antibody against peptidyl-prolyl cis-trans isomerase, matrix, buffer solution, coloring enzyme or fluorescent substance-labeled secondary antibody, coloring substrate and labeled antibody or labeled L4-PHA.

---

3. claims: 1-12 (partially)

A method of diagnosing a cancer comprising measuring the changes of N-linked sugar chains of galectin binding protein in a sample taken from a patient.

A kit for diagnosing cancers by measuring changes of sugar chains and expression of galectin binding protein, composed of antibody against galectin binding protein, matrix, buffer solution, coloring enzyme or fluorescent substance-labeled secondary antibody, coloring substrate and labeled antibody or labeled L4-PHA.

---

4. claims: 1-12 (partially)

A method of diagnosing a cancer comprising measuring the changes of N-linked sugar chains of TIMP-1 in a sample taken from a patient.

A kit for diagnosing cancers by measuring changes of sugar chains and expression of TIMP-1, composed of antibody against TIMP-1, matrix, buffer solution, coloring enzyme or fluorescent substance-labeled secondary antibody, coloring substrate and labeled antibody or labeled L4-PHA.

---

5. claims: 1-12 (partially)



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

A method for diagnosing a cancer comprising measuring the changes of N-linked sugar chains of a protein containing the peptide sequence represented by SEQ. ID. No 6 in a sample taken from a patient.

A kit for diagnosing cancers by measuring changes of sugar chains and expression of a protein containing the peptide sequence represented by SEQ. ID. No 6, composed of antibody against this protein, matrix, buffer solution, coloring enzyme or fluorescent substance-labeled secondary antibody, coloring substrate and labeled antibody or labeled L4-PHA.

---

6. claims: 1-12 (partially)

A method for diagnosing a cancer comprising measuring the changes of N-linked sugar chains of a protein containing the peptide sequence represented by SEQ. ID. No 7 in a sample taken from a patient.

A kit for diagnosing cancers by measuring changes of sugar chains and expression of a protein containing the peptide sequence represented by SEQ. ID. No 7, composed of antibody against this protein, matrix, buffer solution, coloring enzyme or fluorescent substance-labeled secondary antibody, coloring substrate and labeled antibody or labeled L4-PHA.

---

7. claims: 1-12 (partially)

A method for diagnosing a cancer comprising measuring the changes of N-linked sugar chains of a protein containing the peptide sequence represented by SEQ. ID. No 8 in a sample taken from a patient.

A kit for diagnosing cancers by measuring changes of sugar chains and expression of a protein containing the peptide sequence represented by SEQ. ID. No 8, composed of antibody against this protein, matrix, buffer solution, coloring enzyme or fluorescent substance-labeled secondary antibody, coloring substrate and labeled antibody or labeled L4-PHA.

---

8. claims: 1-12 (partially)



The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

A method for diagnosing a cancer comprising measuring the changes of N-linked sugar chains of a protein containing the peptide sequence represented by SEQ. ID. No 9 in a sample taken from a patient.

A kit for diagnosing cancers by measuring changes of sugar chains and expression of a protein containing the peptide sequence represented by SEQ. ID. No 9, composed of antibody against this protein, matrix, buffer solution, coloring enzyme or fluorescent substance-labeled secondary antibody, coloring substrate and labeled antibody or labeled L4-PHA.

---

9. claims: 1-12 (partially)

A method for diagnosing a cancer comprising measuring the changes of N-linked sugar chains of a protein containing the peptide sequence represented by SEQ. ID. No 10 in a sample taken from a patient.

A kit for diagnosing cancers by measuring changes of sugar chains and expression of a protein containing the peptide sequence represented by SEQ. ID. No 10, composed of antibody against this protein, matrix, buffer solution, coloring enzyme or fluorescent substance-labeled secondary antibody, coloring substrate and labeled antibody or labeled L4-PHA.

---

10. claims: 1-12 (partially)

A method for diagnosing a cancer comprising measuring the changes of N-linked sugar chains of a protein containing the peptide sequence represented by SEQ. ID. No 11 in a sample taken from a patient.

A kit for diagnosing cancers by measuring changes of sugar chains and expression of a protein containing the peptide sequence represented by SEQ. ID. No 11, composed of antibody against this protein, matrix, buffer solution, coloring enzyme or fluorescent substance-labeled secondary antibody, coloring substrate and labeled antibody or labeled L4-PHA.

---

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 02 79 3548

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

28-04-2006

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0181928 A	01-11-2001	CA 2405680 A1	01-11-2001
		JP 2003532079 T	28-10-2003
		US 2004053325 A1	18-03-2004
-----			
US 2001010908 A1	02-08-2001	CA 2367125 A1	28-09-2000
		EP 1200113 A2	02-05-2002
		JP 2003524398 T	19-08-2003
		US 2002086320 A1	04-07-2002
		WO 0056352 A2	28-09-2000
-----			
US 5427914 A	27-06-1995	CA 1313496 C	09-02-1993
-----			

专利名称(译)	通过测量与肿瘤发生和转移相关的蛋白质的糖基化变化来诊断癌症的方法和使用该方法诊断癌症的试剂盒		
公开(公告)号	<a href="#">EP1466179A4</a>	公开(公告)日	2006-09-20
申请号	EP2002793548	申请日	2002-12-28
[标]申请(专利权)人(译)	韩国生命工学研究院		
申请(专利权)人(译)	韩国研究学院生物科学与生物		
当前申请(专利权)人(译)	韩国研究学院生物科学与生物		
[标]发明人	KO JEONG HEON HWANG SOO YOUNG SOHN HOSUNG OH SEJEONG LEE JEONG HWA LEE SANG CHUL YOO JONG SHIN LEE DAE SIL		
发明人	KO, JEONG HEON HWANG, SOO YOUNG SOHN, HOSUNG OH, SEJEONG LEE, JEONG HWA LEE, SANG CHUL YOO, JONG-SHIN LEE, DAE-SIL		
IPC分类号	C07K7/06 C07K7/08 G01N21/78 G01N33/53 G01N33/543 G01N33/574		
CPC分类号	G01N33/57469		
优先权	1020010088090 2001-12-29 KR		
其他公开文献	EP1466179B1 EP1466179A1		
外部链接	<a href="#">Espacenet</a>		

摘要(译)

本发明涉及一种通过测量与肿瘤发生和转移相关的蛋白质来诊断癌症的方法，更具体地，提供了一种通过测量基质金属蛋白酶-1 (TIMP-1) 的组织抑制剂的糖基化变化来诊断癌症的方法。使用上述方法诊断癌症的试剂盒。本发明的方法和试剂盒可有效地用于包括结肠癌，胃癌，肺癌和肝癌在内的癌症的敏感诊断。

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
Y	LAFERTE S ET AL: "Monoclonal antibodies specific for human tumor-associated antigen 90K/Mac-2 Binding Protein: Tools to Examine Protein Conformation and Function" JOURNAL OF CELLULAR BIOCHEMISTRY, WILEY-LISS INC, US, vol. 77, no. 4, April 2000 (2000-04), pages 540-559, XP002975310 ISSN: 0730-2312 * abstract * * page 542, column 1, lines 11-33 * * page 546, column 2, lines 33-46 * * page 548, column 1, lines 7-14 * * page 555, column 2, lines 12-21 * * page 556, column 1, lines 13-23 *	1-12	INV. G01N33/574
Y	LAFERTE S ET AL: "CHARACTERIZATION OF A FAMILY OF STRUCTURALLY RELATED GLYCOPROTEINS EXPRESSING BETA1-6-BRANCHED ASPARAGINE-LINKED OLIGOSACCHARIDES IN HUMAN COLON CARCINOMA CELLS" BIOCHEMICAL JOURNAL, PORTLAND PRESS, LONDON, GB, vol. 283, no. 1, 1992, pages 193-201, XP009604873 ISSN: 0264-6021 * abstract * * page 199, column 1, line 13 - line 28 * * page 200, column 2, line 14 - line 24 *	1-12	
X	WO 01/81928 A (ST VINCENT'S HOSPITAL SYDNEY LIMITED; BREIT, SAMUEL; NORBERT; BROWN, D) 1 November 2001 (2001-11-01) * examples 1,7 * * claims 20-22 *	6-12	
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
The Hague		28 April 2006	Adida, A
CATEGORY OF CITED DOCUMENTS * technology reported in abstract * technology reported in description with another document of the same category A: technological background B: non-technological background C: intermediate documents D: theory or principle underlying the invention E: other technical documents, not published or, after the filing date, D: document cited in the application L: document cited for other reasons & : members of the same patent family, corresponding document			